(By Balachander) Illumina Inc. (NASDAQ: ILMN) said a U.S. District Court has agreed to review its earlier decision invalidating certain claims of the company's ‘597 patent.
The U.S. District Court for the Northern District of California granted Illumina's request to file a motion seeking reconsideration of the Court's October 16, 2012 ruling invalidating certain claims of U.S. Patent No. 6,306,597, which is being asserted by Illumina against Complete Genomics Inc. (NASDAQ: GNOM).
[Related -Futures Up After Apple, Inc. (AAPL) Earnings; Maidenform Brands, Inc. (MFB) Surges On Buyout News]
Under the Court's order, Illumina said it is permitted to file briefing asking the Court to reconsider its earlier ruling invalidating claims 14 and 15 of the ‘597 patent.
Illumina said it will seek a January 8, 2013 hearing date on the motion for reconsideration.
"We continue to believe that this patent covers important and novel inventions that Complete Genomics has misappropriated," commented Illumina CEO Jay Flatley.
San Diego, California-based Illumina owns or has exclusive licenses to more than 250 patents granted in the U.S. and many additional patents granted worldwide.
Illumina provides genetic analysis services, including sequencing, genotyping, gene expression, and molecular diagnostics. The company is organized in two business segments: Life Sciences and Diagnostics.
[Related -Stocks Rally On Earnings, Housing Data; Coach (COH) Jumps]
Mountain View, California-based Complete Genomics is a developer of DNA sequencing platform. As of June 30, its backlog was around 4,600 genomes, including about 1,000 genomes booked in the second quarter, representing an aggregate revenue potential of roughly $22 million.
ILMN shares ended at $52.93 on Friday, while GNOM shares closed at $3.14.